PTCT Stock Analysis: Buy, Sell, or Hold?
PTCT - PTC Therapeutics, Inc.
$84.41
2.28 (2.78%)
▲
5d:
+15.2%
30d:
+22.67%
90d:
+30.79%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PTCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PTCT is 8.5% above its trading range ($77.80). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PTCT is 8.5% above its trading range ($77.80). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$135.50
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$84.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PTCT is currently trading at $84.41, which is considered extended relative to its 30-day fair value range of $69.00 to $77.80. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.3) compared to its historical average (26.8). At these levels, the market is pricing in 4.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTCT is in a uptrend. The price is approaching resistance at $85.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $93.93 (+11.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PTCT is in a uptrend. The price is approaching resistance at $85.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $93.93 (+11.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$69.00 -
$77.80
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- BEARISH: Price extended above range (+8.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($93.93)
- NEUTRAL: Market pricing in 4.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$69.00 -
$77.80
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$71.80
Resistance Level
$85.15
Current Trend
Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.33
Wall Street Target
$93.93
(+11.3%)
Revenue Growth (YoY)
-76.8%
Profit Margin
-22.6%
Valuation Premium vs History
+4.2% premium
PE vs Historical
30.3 vs 26.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.2%
(market-implied from PE analysis)
1-Year Target
$87.96
(+4%)
2-Year Target
$91.65
(+9%)
3-Year Target
$95.50
(+13%)
3-Yr Target (if PE normalizes)
(PE: 30→27)
PE COMPRESSION
$84.39
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.3, Growth: 111.9%)
$284.88
(+238%)
Base:
(SPY PE: 21.8, Growth: 111.9%)
$204.59
(+142%)
Bear:
(PE: 18.5, Growth: 111.9%)
$173.90
(+106%)
Share & Embed Analysis
Last updated: June 24, 2026 8:35 PM ET
Data refreshes hourly during market hours. Next update: 9:35 PM
Data refreshes hourly during market hours. Next update: 9:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Matthew B Klein
SELL
2850 shares
2026-04-21
Mark Elliott Boulding
SELL
2265 shares
2026-04-06
Lee Scott Golden
SELL
829 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 63 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 61 BUY |
